article thumbnail

Europe’s pharmaceutical packaging market to value over $35bn by 2028

European Pharmaceutical Review

Europe’s pharmaceutical packaging and labelling market is projected to reach $35.78 billion in 2028, according to a report by Arizton. billion in 2022, the pharmaceutical packaging and labelling market in Europe is expected to expand at a compound annual growth rate (CAGR) of 4.78 percent up to 2028. percent in 2022.

article thumbnail

Boehringer, Lilly’s Jardiance ties to match AZ’s Farxiga with heart failure label

pharmaphorum

It says Farxiga will reach peak sales of $9 billion in 2028, with Jardiance forecast to reach $4.6 The post Boehringer, Lilly’s Jardiance ties to match AZ’s Farxiga with heart failure label appeared first on. billion, assuming a launch for HFrEF this year.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

CD19 CAR-T agents to boost blood cancer market

European Pharmaceutical Review

Breyanzi is approved for DLBCL, and a label expansion is anticipated for expansions into marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL) in 2026 and 2028, respectively. This allows for a large total eligible patient population despite capturing less patient share relative to other CD19 CAR-T agents.

article thumbnail

Merck’s Welireg becomes first drug for rare VHL tumours in US

pharmaphorum

The drug is part of Merck’s efforts to expand its oncology portfolio and reduce its reliance on big-selling cancer immunotherapy Keytruda (pembrolizumab), which is patent protected in the US and Europe until 2028.

article thumbnail

#ASH22: Pirtobrutinib emerges as an option for Richter’s Transformation

Pharmaceutical Technology

Pirtobrutinib has received an FDA orphan drug designation for CLL, and given the true orphan status of RT, regulatory approval with an RT-specific label could be pursued swiftly with this data. GlobalData’s consensus analyst forecast database projects peak sales for pirtobrutinib to reach $892 million by 2028, and $4.8

article thumbnail

Endometriosis market projected to grow at a CAGR of 10% between 2020 and 2030

Pharmaceutical Technology

This therapy is currently in Phase II development and is expected to launch in the US and 5EU in 2027 and 2028, respectively. GlobalData’s report also covers a third pipeline candidate, quinagolide, a dopamine receptor antagonist being developed by Ferring Pharmaceuticals.

article thumbnail

An increasing impact of BCMA-targeting biologics in multiple myeloma

Pharmaceutical Technology

The product labels do not help either; the FDA has approved all such agents for use at the fifth line of therapy or later, while the EMA has adopted the stance of fourth line of therapy or later use for these agents (Figure 1). Should CAR-T cells, or antibodies be used first? Does Blenrep have an efficacy advantage over Tecvayli?